These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38342078)

  • 1. Discovery of novel MAT2A inhibitors by an allosteric site-compatible fragment growing approach.
    Gao F; Ding X; Cao Z; Zhu W; Fan Y; Steurer B; Wang H; Cai X; Zhang M; Aliper A; Ren F; Ding X; Zhavoronkov A
    Bioorg Med Chem; 2024 Feb; 100():117633. PubMed ID: 38342078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A.
    Quinlan CL; Kaiser SE; Bolaños B; Nowlin D; Grantner R; Karlicek-Bryant S; Feng JL; Jenkinson S; Freeman-Cook K; Dann SG; Wang X; Wells PA; Fantin VR; Stewart AE; Grant SK
    Nat Chem Biol; 2017 Jul; 13(7):785-792. PubMed ID: 28553945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of Methionine Adenosyltransferase 2A (MAT2A) as an Anticancer Target: Structure, Function, and Inhibitors.
    Li C; Gui G; Zhang L; Qin A; Zhou C; Zha X
    J Med Chem; 2022 Jul; 65(14):9531-9547. PubMed ID: 35796517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous
    Konteatis Z; Travins J; Gross S; Marjon K; Barnett A; Mandley E; Nicolay B; Nagaraja R; Chen Y; Sun Y; Liu Z; Yu J; Ye Z; Jiang F; Wei W; Fang C; Gao Y; Kalev P; Hyer ML; DeLaBarre B; Jin L; Padyana AK; Dang L; Murtie J; Biller SA; Sui Z; Marks KM
    J Med Chem; 2021 Apr; 64(8):4430-4449. PubMed ID: 33829783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment-Based Design of a Potent MAT2a Inhibitor and
    De Fusco C; Schimpl M; Börjesson U; Cheung T; Collie I; Evans L; Narasimhan P; Stubbs C; Vazquez-Chantada M; Wagner DJ; Grondine M; Sanders MG; Tentarelli S; Underwood E; Argyrou A; Smith JM; Lynch JT; Chiarparin E; Robb G; Bagal SK; Scott JS
    J Med Chem; 2021 May; 64(10):6814-6826. PubMed ID: 33900758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel methionine adenosyltransferase 2A (MAT2A) allosteric inhibitors by structure-based virtual screening.
    Kalliokoski T; Kettunen H; Kumpulainen E; Kettunen E; Thieulin-Pardo G; Neumann L; Thomsen M; Paul R; Malyutina A; Georgiadou M
    Bioorg Med Chem Lett; 2023 Oct; 94():129450. PubMed ID: 37591318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
    Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
    J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAT2B regulates the protein level of MAT2A to preserve RNA N6-methyladenosine.
    Wan X; Zeng W; Fan H; Wang C; Han S; Sun Z; Tang M; Shao J; Liu Y; Fang Y; Jia J; Tang Y; Zhang Y; Zhao B; Fang D
    Cell Death Dis; 2024 Oct; 15(10):714. PubMed ID: 39353892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
    Frau M; Feo F; Pascale RM
    J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability.
    Zhang S; Qing L; Wang Z; Zhang Y; Li Y; Fang H; Liu Y; He H
    J Med Chem; 2023 Apr; 66(7):4849-4867. PubMed ID: 36961373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the methionine-methionine adenosyl transferase 2A- S -adenosyl methionine axis for cancer therapy.
    Guo J; Yang Y; Buettner R; Rosen ST
    Curr Opin Oncol; 2022 Sep; 34(5):546-551. PubMed ID: 35788128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A patent review of MAT2a inhibitors (2018-2021).
    Atkinson SJ; Evans L; Scott JS
    Expert Opin Ther Pat; 2022 Oct; 32(10):1043-1053. PubMed ID: 36043503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
    Kalev P; Hyer ML; Gross S; Konteatis Z; Chen CC; Fletcher M; Lein M; Aguado-Fraile E; Frank V; Barnett A; Mandley E; Goldford J; Chen Y; Sellers K; Hayes S; Lizotte K; Quang P; Tuncay Y; Clasquin M; Peters R; Weier J; Simone E; Murtie J; Liu W; Nagaraja R; Dang L; Sui Z; Biller SA; Travins J; Marks KM; Marjon K
    Cancer Cell; 2021 Feb; 39(2):209-224.e11. PubMed ID: 33450196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Mat2A Uses an Ordered Kinetic Mechanism and Is Stabilized but Not Regulated by Mat2B.
    Bailey J; Douglas H; Masino L; de Carvalho LPS; Argyrou A
    Biochemistry; 2021 Nov; 60(47):3621-3632. PubMed ID: 34780697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Transition-State Structure for Human MAT2A from Isotope Effects.
    Firestone RS; Schramm VL
    J Am Chem Soc; 2017 Oct; 139(39):13754-13760. PubMed ID: 28880543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells.
    Strekalova E; Malin D; Weisenhorn EMM; Russell JD; Hoelper D; Jain A; Coon JJ; Lewis PW; Cryns VL
    Breast Cancer Res Treat; 2019 May; 175(1):39-50. PubMed ID: 30712196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity.
    Xuan YF; Lu S; Ou YJ; Bao XB; Huan XJ; Song SS; Miao ZH; Wang YQ
    Biochem Biophys Res Commun; 2024 Jul; 716():150011. PubMed ID: 38704890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition.
    Fogal V; Michopoulos F; Jarnuczak AF; Hamza GM; Harlfinger S; Davey P; Hulme H; Atkinson SJ; Gabrowski P; Cheung T; Grondine M; Hoover C; Rose J; Bray C; Foster AJ; Askin S; Majumder MM; Fitzpatrick P; Miele E; Macdonald R; Keun HC; Coen M
    Arch Toxicol; 2024 Aug; 98(8):2589-2603. PubMed ID: 38755480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTORC1-independent translation control in mammalian cells by methionine adenosyltransferase 2A and S-adenosylmethionine.
    Alam M; Shima H; Matsuo Y; Long NC; Matsumoto M; Ishii Y; Sato N; Sugiyama T; Nobuta R; Hashimoto S; Liu L; Kaneko MK; Kato Y; Inada T; Igarashi K
    J Biol Chem; 2022 Jul; 298(7):102084. PubMed ID: 35636512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Series of Pyrrolopyridone MAT2A Inhibitors.
    Atkinson SJ; Bagal SK; Argyrou A; Askin S; Cheung T; Chiarparin E; Coen M; Collie IT; Dale IL; De Fusco C; Dillman K; Evans L; Feron LJ; Foster AJ; Grondine M; Kantae V; Lamont GM; Lamont S; Lynch JT; Nilsson Lill S; Robb GR; Saeh J; Schimpl M; Scott JS; Smith J; Srinivasan B; Tentarelli S; Vazquez-Chantada M; Wagner D; Walsh JJ; Watson D; Williamson B
    J Med Chem; 2024 Mar; 67(6):4541-4559. PubMed ID: 38466661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.